The ATOH8 Knockout HeLa Polyclonal Cells consist of a CRISPR/Cas9-edited heterogeneous HeLa cell population carrying targeted disruption of the ATOH8 gene. As a polyclonal knockout product, this model provides a loss-of-function tool that eliminates functional ATOH8 protein while retaining population-level genetic diversity, thus minimizing clonal selection artifacts. It is designed for robust investigation of ATOH8??s role in signaling networks and cellular processes.
The parental HeLa cell line originates from a human cervical adenocarcinoma and is positive for HPV18 sequences, serving as a staple epithelial cancer model. HeLa cells recapitulate key aspects of cervical carcinogenesis, including aberrant signaling and HPV-oncoprotein-driven transformation. Their high proliferation rate and ease of genetic manipulation render them an ideal background for generating knockout models to probe tumor suppressor gene function.
ATOH8 (atonal bHLH transcription factor 8) is a key downstream mediator of TGF-?? and BMP signaling. Upon pathway activation, TGFBR1 phosphorylates SMAD2/3, which partner with SMAD4 and translocate to the nucleus to induce ATOH8 expression. ATOH8 subsequently forms transcriptional complexes with SMAD1, SMAD2/3, and the E-protein TCF3/E47. These complexes directly repress the pro-proliferative ID1 and ID3 genes while promoting the epithelial marker CDH1 (E-cadherin), thereby suppressing EMT and cell proliferation. Through this regulatory axis, ATOH8 acts as a tumor suppressor in multiple tissues, including the cervix.
In the context of HeLa cervical carcinoma cells, ATOH8 deficiency is predicted to exacerbate malignant features such as increased proliferation, motility, and mesenchymal transition. As HeLa cells already exhibit dysregulated TGF-??/BMP pathways due to HPV18 oncogenes, the ATOH8 knockout provides a specific model to assess how loss of this transcription factor contributes to cervical cancer progression. The polyclonal nature of the product allows researchers to evaluate the collective phenotypic impact without the biases of single-cell clones, making it especially useful for studying heterogeneous tumors.
This knockout cell population is suited for diverse investigations, including cancer biology (EMT, metastasis), neurodevelopment (bHLH factor function), and drug discovery screens targeting TGF-??/BMP signaling. Typical experimental readouts include western blotting for ATOH8 and pathway targets, RT-qPCR for ID1, ID3, and CDH1 transcript levels, and chromatin immunoprecipitation to validate ATOH8 binding. Functional assays such as wound healing, transwell migration, and invasion quantify motility changes, while immunofluorescence enables co-localization studies with SMAD partners. For further information or to explore custom cell engineering services, please contact Ascent Research.
